全文获取类型
收费全文 | 104448篇 |
免费 | 9706篇 |
国内免费 | 2634篇 |
专业分类
耳鼻咽喉 | 792篇 |
儿科学 | 2059篇 |
妇产科学 | 2065篇 |
基础医学 | 11961篇 |
口腔科学 | 1920篇 |
临床医学 | 7965篇 |
内科学 | 14978篇 |
皮肤病学 | 1381篇 |
神经病学 | 7148篇 |
特种医学 | 2551篇 |
外国民族医学 | 29篇 |
外科学 | 11195篇 |
综合类 | 12125篇 |
现状与发展 | 6篇 |
预防医学 | 9713篇 |
眼科学 | 963篇 |
药学 | 14974篇 |
109篇 | |
中国医学 | 3493篇 |
肿瘤学 | 11361篇 |
出版年
2023年 | 1927篇 |
2022年 | 2452篇 |
2021年 | 4217篇 |
2020年 | 4202篇 |
2019年 | 4347篇 |
2018年 | 4182篇 |
2017年 | 3908篇 |
2016年 | 3579篇 |
2015年 | 3897篇 |
2014年 | 6459篇 |
2013年 | 7038篇 |
2012年 | 5750篇 |
2011年 | 6415篇 |
2010年 | 5093篇 |
2009年 | 4832篇 |
2008年 | 4928篇 |
2007年 | 4773篇 |
2006年 | 4102篇 |
2005年 | 3591篇 |
2004年 | 3303篇 |
2003年 | 2830篇 |
2002年 | 2305篇 |
2001年 | 1877篇 |
2000年 | 1807篇 |
1999年 | 1570篇 |
1998年 | 1342篇 |
1997年 | 1279篇 |
1996年 | 1146篇 |
1995年 | 1094篇 |
1994年 | 1030篇 |
1993年 | 864篇 |
1992年 | 881篇 |
1991年 | 790篇 |
1990年 | 671篇 |
1989年 | 628篇 |
1988年 | 545篇 |
1987年 | 488篇 |
1986年 | 463篇 |
1985年 | 779篇 |
1984年 | 848篇 |
1983年 | 555篇 |
1982年 | 651篇 |
1981年 | 579篇 |
1980年 | 507篇 |
1979年 | 465篇 |
1978年 | 386篇 |
1977年 | 283篇 |
1976年 | 261篇 |
1975年 | 227篇 |
1974年 | 165篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(5):319-325
BackgroundDespite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outcomes in real-world practice are dismal. We utilized National Cancer Database (NCDB) to explore utilization of multiagent therapy in APL and identify any disparities in treatment in real-world practices.Patients and MethodsNCDB categorizes use of systemic chemotherapy into single agent versus multiagent therapy. Some patients received hormonal therapy, immunotherapy, and unknown therapy; details of these treatments could not be ascertained. We therefore used multiple logistic regression analysis to evaluate effects of covariates on the probability of multiagent therapy use in 6678 patients.ResultsCompared to patients >60 years, patients aged 0 to 18 years (hazard ratio[HR] 3.2, 95% confidence interval [CI] 1.8-5.5, P< .0001), 19 to 40 years (HR 1.6, 95% CI 1.03-2.54, P= .03), and 41 to 60 years (HR 1.6, 95% CI 1.3-1.9, P< .0001) were more likely to receive multiagent therapy. Patients with Charlson comorbidity index (CCI) of 0 (HR 1.6, 95% CI 1.2-2.3, P= .001) and CCI of 1 (HR 1.4, 95% CI 1.0-1.9, P= .04) had a higher likelihood of receiving multiagent therapy than patients with CCI ≥ 3. Patients treated at academic cancer centers, compared to those treated at community cancer center (HR 0.5, 95% CI 0.3-0.7, P= .001), comprehensive community cancer center (HR 0.7, 95% CI 0.6-0.8, P< .0001), and integrated network cancer center (HR 0.8, 95% CI 0.6-0.9, P= .02) were more likely to be treated with multiagent therapy. Compared to the patients with private insurance, those with Medicaid had increased likelihood (HR 1.2, 95% CI 1.0-1.4, P= .04) whereas uninsured patients had a lower likelihood of receiving multiagent therapy (HR 0.6, 95% CI 0.5-0.8, P= .0005).ConclusionTo our knowledge, this study is the first and the largest scale analysis of treatment practices in APL in real-world practices. Our findings highlight significant disparities in treatment of APL based on age, insurance, and health-system factors. 相似文献
3.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
4.
5.
目的探讨关节镜下半月板成形术(AMP)对膝关节半月板损伤患者血清疼痛因子、一氧化氮(NO)、透明质酸(HA)及关节活动度的影响。方法选取2019年5月—2020年12月收治的90例膝关节半月板损伤为研究对象,根据治疗方法不同分为对照组和治疗组,每组45例。对照组接受保守治疗,治疗组行AMP治疗。比较两组的临床疗效,治疗前后的血清前列腺素E2(PGE2)、5-羟色胺(5-HT)、NO、HA、疼痛视觉模拟评分法(VAS)评分和膝关节活动度。记录两组治疗并发症发生情况。结果治疗组疗效优良率高于对照组(P<0.05)。治疗后,两组血清PGE2、5-HT、NO、HA水平均较治疗前下降,且治疗组低于对照组(P<0.05)。治疗后1、2、3、4周,两组VAS评分均较治疗前降低,且治疗组低于对照组(P<0.05)。治疗后,两组膝关节屈伸活动度均较治疗前升高,且治疗组高于对照组(P<0.05)。两组并发症发生率比较差异无统计学意义(P>0.05)。结论AMP对膝关节半月板损伤疗效良好,可减少疼痛因子生成,控制NO、HA水平,提高关节活动度。 相似文献
6.
Matthias Knefel PhD Elisabeth L. Zeilinger PhD Simone Lubowitzki PhD Katharina Krammer MSc Matthias Unseld MD Rupert Bartsch MD Thorsten Fuereder MD Ulrich Jäger MD Barbara Kiesewetter MD Maria Krauth MD Markus Raderer MD Philipp B. Staber MD Peter Valent MD Alexander Gaiger MD 《Cancer》2023,129(21):3466-3475
Background
Survival in cancer patients is associated with a multitude of biological, social, and psychological factors. Although it is well established that all these factors add to overall mortality, it is not well understood how the predictive power of these parameters changes in a comprehensive model and over time.Methods
Patients who attended the authors’ outpatient clinic were invited to participate. The authors followed 5180 mixed cancer patients (51.1% female; mean age, 59.1 years [SD = 13.8]) for up to 16 years and analyzed biological (age, sex, cancer site, anemia), psychological (anxiety, depression), and social variables (marital status, education, employment status) potentially predicting overall survival in a Cox proportional hazards model.Results
The median survival time for the entire sample was 4.3 years (95% confidence interval, 4.0–4.7). The overall survival probabilities for 1 and 10 years were 76.8% and 38.0%, respectively. Following an empirical approach, the authors split the time interval into five periods: acute, subacute, short-term, medium-term, and long-term. A complex pattern of variables predicted overall survival differently in the five periods. Biological parameters were important throughout most of the time, social parameters were either time-independent predictors or tended to be more important in the longer term. Of the psychological parameters, only depression was a significant predictor and lost its predictive power in the long-term.Conclusions
The findings of this study allow the development of comprehensive patient-specific models of risk and resilience factors addressing biopsychosocial needs of cancer patients, paving the way for a personalized treatment plan that goes beyond biomedical cancer care. 相似文献7.
8.
《Vaccine》2022,40(18):2525-2527
9.
《International journal of oral and maxillofacial surgery》2022,51(3):314-322
While Merkel cell carcinoma (MCC) of the head and neck is highly malignant, it remains poorly characterized due to its rarity. The purpose of this study was to examine prognostic factors for overall survival (OS) and disease-specific survival (DSS) in patients with MCC of the head and neck region. The Surveillance, Epidemiology and End Results registry was reviewed for patients diagnosed between 1984 and 2016 with histologically confirmed, primary MCC of the head and neck region. A total of 2818 patients met the inclusion criteria, with a median age at diagnosis of 77 years. At five and 10 years, respectively, the OS was 42.4% and 25.1% and the DSS was 67.9% and 64.1%. Multivariate Cox analysis indicated that predictors of decreased DSS included age at diagnosis ≥75 years, white race, increasing tumor spread, lymph node involvement and either the lip or the scalp/neck as a primary site. When adjusting for the aforementioned factors, tumor depth was not found to be a prognostic factor for DSS. We anticipate these results will help clinicians to counsel patients regarding expectations and potential prognosis. 相似文献
10.